156 related articles for article (PubMed ID: 5025912)
1. High doses of spironolactone in the treatment of liver cirrhosis with ascites.
Papadoyanakis N; Darsinos J; Alexandrou K; Karli J
Br J Clin Pract; 1972 Jan; 26(1):27-32. PubMed ID: 5025912
[No Abstract] [Full Text] [Related]
2. Refractory ascites: can it be defined only by the response to furosemide and spironolactone?
Kalambokis G; Tsianos EV
Liver Int; 2010 Oct; 30(9):1394; author reply 1395-6. PubMed ID: 20738777
[No Abstract] [Full Text] [Related]
3. [Biological factors influencing response to diuretics in patients with cirrhosis and ascites].
Lenaerts A; Codden T; Henry JP; Van Cauter J; Meunier JC; Ligny G
Gastroenterol Clin Biol; 2001 Mar; 25(3):268-72. PubMed ID: 11395674
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia--a randomized, double-blind, placebo-controlled study.
Ginès P; Wong F; Watson H; Terg R; Bruha R; Zarski JP; Dudley F;
Aliment Pharmacol Ther; 2010 Apr; 31(8):834-45. PubMed ID: 20102356
[TBL] [Abstract][Full Text] [Related]
5. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety.
Santos J; Planas R; Pardo A; Durández R; Cabré E; Morillas RM; Granada ML; Jiménez JA; Quintero E; Gassull MA
J Hepatol; 2003 Aug; 39(2):187-92. PubMed ID: 12873814
[TBL] [Abstract][Full Text] [Related]
6. [Prolonged treatment of ascitic cirrhosis by the combination of a saldiuretic and a spironolactone].
Tolot F; Dechavannes M; Fiere D
Lyon Med; 1966 Jan; 215(1):29-35. PubMed ID: 5904663
[No Abstract] [Full Text] [Related]
7. [Treatment of ascites in hepatic cirrhosis].
Arroyo JL; Bueno J; Rivero A; Lucas I; Ortiz de Landazuri E
Rev Esp Enferm Apar Dig; 1966 Nov; 25(9):1021-46. PubMed ID: 5997895
[No Abstract] [Full Text] [Related]
8. [Rational use of diuretics in hepatic cirrhosis].
Vagge R; Cavatorta F; Queirolo C
G Clin Med; 1983; 64(3-4):116-23. PubMed ID: 6884638
[No Abstract] [Full Text] [Related]
9. [The combination of corticoids, spironolactone, salidiuretics and mannitol according to a particular schema of treatment of ascitic cirrhosis].
Colucci CF
Schweiz Med Wochenschr; 1966 May; 96(20):660-5. PubMed ID: 5988706
[No Abstract] [Full Text] [Related]
10. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system.
Pérez-Ayuso RM; Arroyo V; Planas R; Gaya J; Bory F; Rimola A; Rivera F; Rodés J
Gastroenterology; 1983 May; 84(5 Pt 1):961-8. PubMed ID: 6339312
[TBL] [Abstract][Full Text] [Related]
11. [Use of repeat courses of unithiol in the complex treatment of liver cirrhosis].
Khvorostinka VN; Teslenko VG; Khvisiuk SS; Kosenko NP; Borisenko GV
Vrach Delo; 1986 Mar; (3):75-9. PubMed ID: 3087063
[No Abstract] [Full Text] [Related]
12. [Therapeutic program for ascites. Recommendations from the Swedish Society of Gastroenterology and Gastrointestinal Endoscopy].
Lööf L; Prytz H; Söderlund C; Wallerstedt S
Lakartidningen; 2001 Dec; 98(49):5649-52, 5655. PubMed ID: 11783052
[TBL] [Abstract][Full Text] [Related]
13. High Dose Oral Furosemide with Salt Ingestion in the Treatment of Refractory Ascites of Liver Cirrhosis.
Yakar T; Demir M; Dogan O; Parlakgumus A; Ozer B; Serin E
Clin Invest Med; 2016 Dec; 39(6):27502. PubMed ID: 27917793
[TBL] [Abstract][Full Text] [Related]
14. Attenuation by spironolactone of the magnesiuric effect of acute frusemide administration in patients with liver cirrhosis and ascites.
Stergiou GS; Mayopoulou-Symvoulidou D; Mountokalakis TD
Miner Electrolyte Metab; 1993; 19(2):86-90. PubMed ID: 8377729
[TBL] [Abstract][Full Text] [Related]
15. Spironolactone and frusemide in cirrhosis with ascites.
Sadikali F
Br J Clin Pract; 1973 Jun; 27(6):222-4. PubMed ID: 4582147
[No Abstract] [Full Text] [Related]
16. Comparison of azosemide and furosemide in ascitic patients without and during administration of spironolactone.
Radó JP; Molnár Z; Hartai A; Gercsák G
Int J Clin Pharmacol Ther Toxicol; 1982 Nov; 20(11):532-7. PubMed ID: 7174156
[TBL] [Abstract][Full Text] [Related]
17. Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites.
Goto A; Terai S; Nakamura M; Matsumoto M; Sakaida I
Clin J Gastroenterol; 2015 Feb; 8(1):47-51. PubMed ID: 25475138
[TBL] [Abstract][Full Text] [Related]
18. [Diuretic treatment and metabolic alkalosis in ascitic liver cirrhosis].
Grassi V; Porcellati C; Corea L; Todisco T
Minerva Nefrol; 1968; 15(4):258-60. PubMed ID: 5745815
[No Abstract] [Full Text] [Related]
19. Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study.
Thuluvath PJ; Maheshwari A; Wong F; Yoo HW; Schrier RW; Parikh C; Steare S; Korula J
Aliment Pharmacol Ther; 2006 Sep; 24(6):973-82. PubMed ID: 16948809
[TBL] [Abstract][Full Text] [Related]
20. [Anti-aldosterone therapy in cirrhosis of the liver with ascites].
Loginov AS; Berezov VM
Sov Med; 1967 Feb; 30(2):39-42. PubMed ID: 5597952
[No Abstract] [Full Text] [Related]
[Next] [New Search]
